Our experienced staff of organic medicinal chemists, analytical experts and pharmacologists provides comprehensive drug discovery and evaluation services to small, large, and even virtual pharmaceutical companies.

We provide synthesis, structure proof, analytical methods, in addition to SAR, QSAR and computer aided drug design services.

Contact Us for further information.

Announcements

A novel synthetic antibacterial drug for Clostridium difficile-associated infections (CDI)
We have discovered potent and selective synthetic bactericidal compounds that inhibit multiple strains of the anaerobe Clostridium difficile (Cdiff) in culture, and that protect hamsters from Cdiff-associated diarrhea and colitis and death, including those from recurrent infections. Learn more by downloading our press release.

April 7, 2014 — A novel synthetic antibacterial drug for Clostridium difficile-associated infections (CDI)

Anti-Infective R & D Partnership, L. P. (“the Partnership”) is offering two hundred (200) Limited Partnership units at $50,000 per Unit.
Learn more about this opportunity by downloading our memorandum

April 9, 2014 — Limited Partnership Interests